In a syngeneic mouse model, the administration of anti–VEGFR-2 chimeric antigen receptor (CAR) and IL-12–co-transduced T cells directly into the tumor site modified the immune suppressive environment by ablating systemic and intra-tumoral VEGFR-2+ myeloid-derived suppressor cells (MDSCs) [30]. This evidence concerns the gene KDR and neoplasm.